Trustiva (Emtricitabine/Tenofovir/Efavirenz)

Introduction

Trustiva is a fixed-dose combination tablet containing Emtricitabine (200 mg), Tenofovir Disoproxil Fumarate (300 mg), and Efavirenz (600 mg). It’s an antiretroviral drug utilized to treat HIV-1 disease for adolescents and adults who weigh at least 35 kilograms. Trustiva blends three effective drugs from various classes of antiretrovirals into an all-day regimen to slow viral replication, boost the immune system, and decrease mortality due to HIV.

Composition and Dosage Form

• Emtricitabine: 200 mg
• Tenofovir Disoproxil Fumarate (TDF): 300 mg
• Efavirenz: 600 mg
• Dosage Form: Oral film-coated tablet
• Packaging: Typically available in blister packs or bottles containing 30 tablets

Mechanism of Action

Trustiva is a combination of three active components that each focuses on HIV replication using different methods:

1. Emtricitabine: A nucleoside reverse transcriptase inhibitor (NRTI) that resembles natural nucleosides is integrated into the viral genome and results in chain termination when it is reverse transcribed.
2. Tenofovir Disoproxil Fumarate (TDF): Another NRTI, similar to the one mentioned above, works in that it blocks reverse transcriptase, stopping the transformation of RNA from viruses into DNA.
3. Efavirenz: A non-nucleoside reverse transcriptase inhibitor (NNRTI) that is a direct binder to reverse transcriptase at a location that is distinct from the binding area and causes allosteric inhibition of the enzyme.

Together, they inhibit the replication of HIV by inhibiting the reverse transcriptase enzyme. This is essential to the HIV cycle of life, thus decreasing the load of HIV and preserving immune function.

Indications

Trustiva is indicated for:

• Treatment of HIV-1 infection in adults and adolescents (≥35 kg).
• As part of the combination therapy against HIV (cART).
• First-line treatment for non-treatment patients.
• Treatment for patients who are blocked by antiretroviral regimens with the individual ingredients.

Dosage and Administration

• Recommended Dose: A tablet every day. It is best taken on an empty stomach or before bedtime to minimize side effects on the central nervous system.
• Tablets must be taken whole and should not be chewed, broken, or crushed.
• The strictness of the daily dose routine is essential for the best control of the virus and protection against resistance.
• Dosage adjustments are not typically necessary based on your weight or age (≥35 kg).

Special Considerations:

• Patients suffering from renal impairment need surveillance and possibly dosage modifications due to the tenofovir’s kidney excretion.
• Stop abruptly and without consulting your physician to ensure that you do not suffer from viral rebound.

Pharmacokinetics

• Absorption: Efavirenz is absorbed well and has maximum plasma concentrations within 3-5 hours following the dosage. Emtricitabine and Tenofovir can also able to reach their peak concentrations in about 1-2 hours.
• Metabolism: The majority of Efavirenz’s metabolites are carried out by liver enzymes, CYP2B6 and CYP3A4. Tenofovir and Emtricitabine are eliminated in a form that is not altered by the kidneys.
• Half-life: Efavirenz ~40-55 hours; Emtricitabine ~10 hours; Tenofovir ~17 hours.
• Excretion: Primarily, renal in the case of Emtricitabine and Tenofovir, as well as biliary and renal routes for Efavirenz and its metabolites.

Contraindications

• There is an established hypersensitivity to any ingredient of Trustiva.
• Severe hepatic impairment (due to Efavirenz metabolism).
• Drugs that is highly dependent on CYP3A4 for clearance could affect each other adversely.
• The mother and baby require an in-depth risk-benefit analysis; Efavirenz is generally avoided during the first trimester because of the possibility of teratogenicity.

Warnings and Precautions

• Neuropsychiatric Effects: Efavirenz may cause dizziness, nightmares, insomnia, as well as depression or psychosis. Pay attention, particularly during the initial weeks.
• Liver Toxicity: Regularly monitor liver function tests and take care of patients who have Hepatitis B or C co-infection.
• Renal Toxicity: Tenofovir is known to cause renal impairment. Monitor renal function, especially for patients who have pre-existing renal illness.
• Bone Mineral Density: Tenofovir long-term usage can reduce the density of bone minerals.
• Immune Reconstitution Syndrome: The symptoms of infections that are opportunistic may be present after the start of the treatment.
• Drug Interactions: Efavirenz is a CYP450 stimulator and could decrease the effectiveness of other medications that are processed via this pathway.

Potential Side Effects

Common side effects:

• Dizziness, headache
• Fatigue, insomnia
• Nausea, diarrhea
• Rash
• Abnormal dreams or vivid nightmares (Efavirenz-related)
• Elevated liver enzymes
• Lipid abnormalities

The most serious side effects require urgent medical attention:

• Severe rash or Stevens-Johnson Syndrome
• Severe depression or suicidal thoughts
• Signs of lactic acidosis or hepatomegaly with steatosis
• Renal dysfunction or failure

Drug Interactions

• CYP450 Inducers/Inhibitors: Efavirenz can affect many medications via the CYP450 system. Adjusting dosage or alternative therapies might be necessary.
• Other Antiretrovirals: It is important to take care of the patient when combining with protease inhibitors or Integrase inhibitors.
• Anticonvulsants, Rifampin, Hormonal Contraceptives: Could reduce effectiveness or even increase the toxicity.
• Always inform your physician about all supplements, medications, and herbal supplements.

Use in Special Populations

• Pregnancy: Only use if the benefits are greater than the risk; stays clear of Efavirenz during the first trimester if it is.
• Pediatrics: Accepted by patients who weigh more than 35 kg.
• Geriatrics: Lack of data; take care when using.
• Renal Impairment: Check kidney function and modify diet if required.
• Hepatic Impairment: Avert your eyes when you take Efavirenz.

Storage Instructions

• Maintain a temperature of 30°C (86°F) in an area that is dry and secured from light and moisture.
• Make sure that the area is safe for young children.
• Use only after the expiration date.

Patient Counseling Information

• It is recommended to take Trustiva at least once a day and preferably in the evening on an empty stomach.
• Don’t miss doses. Treatment adherence is essential to stop the spread of viral infections.
• Notify anyone of mood changes, such as a severe rash or other neurological symptoms, as soon as you notice them.
• Beware of recreational and alcohol-related drugs, which can cause worse negative effects.
• Tell your doctor about any other supplements and medications.
• Maintain regular surveillance and check-ups to check kidney function, liver, and viral load.

Clinical Efficacy

Trustiva’s fixed-dose, once-daily regimen makes treatment easier and helps improve adherence. Clinical trials have confirmed its efficacy in providing long-lasting antiviral suppression, improved immune function (increased count of CD4), and a lower rate of resistance develops when administered according to the prescription.

Summary

Trustiva (Emtricitabine/Tenofovir Disoproxil Fumarate/Efavirenz) is a cornerstone therapy in the management of HIV-1 infection. Combining three effective drugs that target viral replication provides a highly effective and simple, one-time regimen that increases adherence of patients and enhances the long-term results. A thorough education of patients and frequent assessment ensure that the maximum benefit is achieved and reduce the risk associated with treatment.